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Abstract
Introduction Adverse efects of medications taken during pregnancy are traditionally studied through post-marketing preg-
nancy registries, which have limitations. Social media data may be an alternative data source for pregnancy surveillance 
studies.
Objective The objective of this study was to assess the feasibility of using social media data as an alternative source for 
pregnancy surveillance for regulatory decision making.
Methods We created an automated method to identify Twitter accounts of pregnant women. We identiied 196 pregnant 
women with a mention of a birth defect in relation to their baby and 196 without a mention of a birth defect in relation to their 
baby. We extracted information on pregnancy and maternal demographics, medication intake and timing, and birth defects.
Results Although often incomplete, we extracted data for the majority of the pregnancies. Among women that reported birth 
defects, 35% reported taking one or more medications during pregnancy compared with 17% of controls. After accounting 
for age, race, and place of residence, a higher medication intake was observed in women who reported birth defects. The rate 
of birth defects in the pregnancy cohort was lower (0.44%) compared with the rate in the general population (3%).
Conclusions Twitter data capture information on medication intake and birth defects; however, the information obtained 
cannot replace pregnancy registries at this time. Development of improved methods to automatically extract and annotate 
social media data may increase their value to support regulatory decision making regarding pregnancy outcomes in women 
using medications during their pregnancies.
Key Points 
Social media data can provide information on medica-
tion intake and birth defects; however, the information 
obtained cannot replace pregnancy registries at this time. 
At present, these data are incomplete but may still be 
useful to supplement pregnancy registry data.
Future research is necessary to reine eforts and uses of 
social media data to support regulatory decision making 
regarding pregnancy outcomes with recently approved 
drugs used in women of child-bearing age.
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1 Introduction
New pharmaceutical products undergo rigorous testing 
prior to approval. However, data on safety during preg-
nancy are sparse, particularly for new products [1], as 
clinical trials often exclude women who are pregnant or 
breastfeeding because of ethical implications. Up to 80% 
of pregnant women take at least one prescribed or over-
the-counter (OTC) medication during their pregnancy [2]. 
Further, many pregnancies are unplanned, for example in 
USA, almost half of pregnancies are unplanned [3], thus 
unintended fetal exposure to medications during criti-
cal periods of development is likely to occur [4]. There-
fore, evidence of safety during pregnancy relies on other 
sources of data, such as observational studies in the post-
market setting.
The most common type of pregnancy surveillance stud-
ies are traditional pregnancy registries [5], which have 
been the standard for post-marketing pregnancy surveil-
lance. There are many known disadvantages with regis-
tries, including a lack of an appropriate comparator group 
to estimate background rates, selective loss to follow-up, 
and low rates of recruitment [6–10]. The routine use of 
ultrasounds and early prenatal screening challenges true 
prospective enrollment into traditional registries and may 
bias results of the registry [9]. Even with eforts made to 
enroll women as early as possible in the pregnancy (sev-
enth or eighth week of gestation) [1], any adverse drug 
efects during early pregnancy may be missed [1]. Finally, 
the frequent inability to have signiicant statistical asso-
ciations within pregnancy registries is primarily owing to 
poor patient enrollment and the few birth defects recorded 
in these observational studies. Hence, although pregnancy 
registries have adequate statistical power to detect signals 
of major-risk teratogenicity (birth defect rate of 25%), they 
are not powered to detect signals of moderate-risk terato-
gens [11, 12] or speciic birth defects [9]. These limita-
tions, together with the knowledge that one data source is 
unlikely to be suicient to provide enough information on 
potentially rare outcomes, have led researchers and regula-
tory agencies to identify supplementary sources of data for 
evaluating the safety of medicines in pregnancy.
Alternative sources for pregnancy surveillance include 
population-based surveillance registers, electronic health-
care records, and administrative claims databases, and 
studies within these databases have provided key evidence 
of drug exposures, pregnancy outcomes, and birth defects 
[13–20]. However, these sources lack data on OTC medi-
cines and lifestyle factors and prescription ills are used 
as a surrogate to medication intake. Further, population-
based surveillance registers with linkage capabilities 
between the mother and baby are not available in USA. 
Therefore industry-sponsored voluntary registries focused 
on single drugs or group of drugs associated with a disease 
(e.g., human immunodeiciency virus, epilepsy) remain the 
primary source of pregnancy safety surveillance [21, 22].
Social media are another potential emerging source of 
data for use in pregnancy surveillance. Social media data 
include information on lifestyle factors collected in women 
prior to pregnancy and early in the irst trimester, when the 
risk of congenital abnormalities is highest [23]. Other advan-
tages could include prospective data collection in real time 
and throughout pregnancy and the capture of information 
on OTC medicines and lifestyle factors, such as smoking 
and alcohol usage that may be associated with deleterious 
pregnancy outcomes. In unveriied claims, it is postulated 
that the power of social media to link rare, strikingly unan-
ticipated fetal abnormalities as seen during the “thalidomide 
storm” to drug usage would have taken only 5–7 days [24].
We selected Twitter for this pilot study as Twitter is a 
very popular social media source, is publically available, 
and our prior work has assessed the feasibility of identify-
ing pregnant women who actively use Twitter [25]. For this 
study, we proposed that publicly available tweets throughout 
the full timeline of a pregnancy could be annotated, and 
potential useful information on drug utilization and birth 
defects obtained. We hypothesized that much of the data 
routinely collected in registries, such as basic demograph-
ics, medicine intake, and birth defects, could be obtained 
from the social media posts throughout the full term of a 
pregnancy, and that this annotation could be performed auto-
matically in the future. With data from these timelines, we 
assessed the feasibility of constructing a nested case-control 
study within a cohort of pregnant women to quantify the 
association between pregnancy-related exposure and birth 
defects.
2  Methods
The methodology followed for this study needed to address 
the problems of identifying women having a baby with a 
birth defect using primarily automated methods. Given 
the rare occurrence of birth defects, case-control studies 
nested within large populations are the preferred approach 
for the evaluation of speciic pregnancy outcomes [6]. 
Thus, to identify the case and control groups from social 
media, we first needed to identify pregnant women 
amongst the millions of Twitter users. Our initial work was 
focused on this, detecting users to add to our pregnancy 
database via a single tweet announcement [25]. Our auto-
matic classiication system achieves an  F1-score of 0.88 
for identifying pregnancies. The  F1-score is computed as 
2 × (Precision × Recall)/(Precision + Recall), where preci-
sion is True Positives/(True Positives + False Positives), 
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and recall is True Positives/(True Positives + False Nega-
tives). Once pregnant users are identiied, all of their pub-
licly available tweets (their “timeline”) were collected. A 
total of 112,429 users were identiied and their timelines 
collected. A method for estimating the number of time-
lines that encompasses the user’s pregnancy was devel-
oped [26], resulting in a total of 44,825 timelines in our 
database.
2.1  Selection of the Cohorts
A birth defects cohort (cases) was created by retrieving 
and annotating tweets from the pregnancy database that 
mention birth defects. This method, which we summa-
rize in the remainder of this sub-section, is described in 
further detail in another publication [26]. As Fig. 1 illus-
trates, we manually compiled a lexicon of approximately 
650 terms referring to birth defects (Penn Social Media 
Lexicon of Birth Defects), based on published reports, 
guidelines, and the Uniied Medical Language System 
[27–31], and semi-automatically generated lexical vari-
ants of these terms (e.g., misspellings). To retrieve tweets 
containing (variants of) the terms, we implemented hand-
crafted regular expressions in a series of database queries. 
We post-processed the retrieved tweets by removing those 
containing user names and URLs matched by the regular 
expressions. With this retrieval method, a total of 16,822 
tweets (posted by 5923 users) were collected, with a recall 
of 0.95. The tweets were annotated by two annotators. 
We developed annotation guidelines to distinguish three 
classes of tweets, summarized as follows: 
Defect (+)  The tweet refers to a person who has a 
birth defect and identiies that person 
as the Twitter user’s child
Possible Defect (?)  The tweet is ambiguous about whether 
a person referred to has a birth defect 
and/or is the Twitter user’s child
Non-defect (−)  The tweet does not indicate that a 
person referred to has or may have a 
birth defect and is or may be the Twit-
ter user’s child
The annotators’ inter-annotator agreement (Cohen’s 
kappa) was high (κ = 0.79). In total, 765 (4.55%) tweets were 
annotated as “defect,” 877 (5.21%) tweets were annotated as 
“possible defect,” and 15,180 (90.24%) tweets were anno-
tated as “non-defect.” The annotations directed us to the 
timelines of the users who posted them, for an inclusion/
exclusion analysis to determine a inal cohort. Users were 
excluded from the cohort if we could not determine if they 
were the parent of a child with a birth defect, or if there were 
no tweets available during the pregnancy with a birth defect 
outcome. First, we analyzed the timelines of the 359 users 
who posted a “possible defect” tweet (without also post-
ing a “defect” tweet), and determined that 142 (39.55%) of 
them were indeed the parent of a child with a birth defect. 
Then, we analyzed the timelines of these 142 users and the 
287 users who posted a “defect” tweet, and determined 
that 196 (45.69%) of the 429 timelines encompass tweets 
from the timeframe of the pregnancy with a birth defect 
outcome. Thus, we identiied 196 users for our birth defects 
(case) cohort. For this study, the timelines of the 196 women 
reporting a birth defect (cases) were matched on timing of 
Fig. 1  Worklow of tweet collection, tweet annotation, and timeline analysis for selecting the birth defects (case) cohort
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pregnancy to timelines of 196 women not reporting any birth 
defects (controls) in the pregnancy database.
2.2  Data Preparation
All tweets mentioning birth defects were automatically iden-
tiied using the lexical approach presented in [26]. For this 
project, we retrieved the timelines of the users corresponding 
to these tweets and tagged recognizable medication names to 
facilitate the manual annotation process of the timelines. A 
set of 37 drug names, including variants and misspellings, 
was already annotated in our timelines and manually clas-
siied into intake, possible intake, or no intake categories. 
For greater coverage of medications, we extended this initial 
set of drugs with the list of drug names published in the 
Drugs@FDA database.1 We added lexical variants (possible 
misspellings) of these drug names and tagged the names in 
the timelines. All drug mentions found in the tweets during 
this last process were then automatically classiied as intake, 
possible intake, or no intake using our in-house classiier 
[32]; this pre-annotating step speeds up manual curation. 
In our past work [32], inter-annotator agreement (Cohen’s 
kappa) for manually identifying medication intake was very 
high (κ = 0.88). Finally, all mentions of gestational ages were 
automatically pre-annotated and tagged in the timelines [33].
2.2.1  Annotation of Exposures of Interest
To analyze the data for the cases and controls, we irst 
needed to manually annotate the timelines for exposures of 
interest whenever we did not have any automatic method of 
doing so, and to corroborate any information tagged auto-
matically. Exposures of interest were; maternal age, due 
date, place of residence, race/ethnicity, medicine intake at 
irst, second, and third trimester, and birth defects. We cre-
ated an annotation guideline with examples, and selected 
the General Architecture for Text Engineering environment 
for annotation [34].
We annotated all tweets in the timeline of the pregnancy, 
deined as the time of pregnancy plus 1 month before and 
1 month after. Within this timeframe, we annotated all men-
tions of gestational ages, any indications of the due date of 
delivery, the pregnancy outcome, and the date of birth of 
the child. We also annotated each tweet mentioning a drug 
name listed in the Drugs@FDA database and if the drug 
was taken (or possibly taken) by trimester of the pregnancy. 
We annotated all mentions of birth defects and then classi-
ied them under their corresponding Medical Dictionary for 
Regulatory Activities categories. Annotation guidelines are 
provided as a supplement.
Maternal age was often given in reference to a birthday 
such as “I’m 24 on Friday” or ‘Only 2 hours until I’m 21 and 
legal!’ Others mentioned their age in passing “I’m 22 but 
look 26” or “Gosh you would think I would know that at 20.” 
Where only approximations of age were given (e.g., women 
indicated that they were in their 20s or 30s), we categorized 
these as missing data.
The country of residence of the woman was often pre-
sent in the proile information (e.g., “Proud Colombian,” 
“Texas,” or “Bangor, Wales”) or stated in a post. Race was 
also sometimes explicitly stated: “Just because I’m Hispanic 
…” or “I’m not African-American I’m black American.”.
Medications were categorized based on the available evi-
dence of risks associated with taking particular medicines 
while pregnant as per the Australian categorization system.2 
We selected this categorization system as there is no lan-
guage barrier, it has greater granularity of classiications 
(with seven categories A, B1, B2, B3, C, D, X), is easy to 
use, and is up to date. Some comments were not possible to 
classify as there was insuicient detail to identify the medi-
cation, such as “My pain meds aren’t working anymore,” or 
“Got to take antibiotics for …”. Medications were grouped 
into ‘probably safe’ or ‘potentially risky’ to help facilitate 
the analysis and compare with previous studies. [35] The 
‘probably safe’ category consisted of A, B1, and B2 clas-
siications and the ‘potentially risky’ category consisted of 
B3, C, D, and X.
Although in most instances the medications were named 
in the tweets, we made a concerted efort not to publish the 
individual drug names in this article. This was because the 
study was a feasibility study to test the methodologies using 
social media. Given the exploratory nature of these meth-
ods, we chose not to study individual drug products and 
raise concern over spurious safety signals without further 
evidence of causality. To gather additional information on 
drug classes would require additional data mining and natu-
ral language processing information that was not collected 
initially and is beyond the scope of this project.
Most of the comments on medication intake refer to when 
the medication was consumed either directly or indirectly: 
“4 mg of X four hours ago and still got a headache,” “taken 
X and now of to bed.” We were able to ascertain the timing 
of the medication intake for the users by the date of the post 
and then assess whether the intake was from the irst, second, 
or third trimester. Many women gave the actual due date for 
their baby or provided information from which the due date 
could be calculated “I am due on the 24th of February” or 
1 Available at https ://www.fda.gov/Drugs /Infor matio nOnDr ugs/
ucm13 5821.htm.
2 Available at https ://www.tga.gov.au/presc ribin g-medic ines-pregn 
ancy-datab ase.
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“I’m due a week today.” There were many references to the 
length of term of the pregnancy (either by how far into the 
pregnancy they were or by how long the pregnancy had left). 
For instance, “I’m 24 weeks today” or “6 more weeks to 
my due date.” From gestational age annotations, the annota-
tor could calculate an estimated pregnancy conception date 
using an Internet pregnancy calculator.3 From this informa-
tion, exposure to medications could be categorised as in the 
irst, second, or third trimester.
2.3  Statistical Methods
Using the cc command in Stata, we estimated the odds ratios 
for each risk factor. The conidence intervals were estimated 
by the exact method. For the type of medication, we calcu-
lated an overall p value using a chi-squared test for a con-
tingency table, as these are not independent variables but 
diferent categories of the same variable. A p value < 0.05 
was considered statistically signiicant.
To check whether matching was informative, the analy-
sis for any medication use was also carried out by logistic 
regression, both ignoring the matching and allowing for 
matching using robust standard errors. Results were not 
appreciably altered and, therefore, we conducted an analysis 
without matching to minimize the impact of missing data.
To check whether other available risk factors (age, eth-
nicity, country of residence) could explain the relationship 
between birth defects and medication, logistic regression 
was used. We excluded women for whom any of these 
variables were missing and for ethnicity and residence cat-
egories with fewer than ten women, we used the “other” 
category.
3  Results
The mean number of posts per pregnancy timeline in the 
cases was 2903, varying from 70 to 15,271 posts. The aver-
age number of posts per woman in the control group was 
lower at 2582 (range 19–9142). For comparison, in the entire 
database of 112,429 timelines, the mean number of posts 
per person was 3850 (range: 2–80,023 posts). Annotations 
of each of the 196 cases and 196 control pregnancy timeline 
took an average of 2 h.
The rate of birth defects in our cohort of pregnant women 
(cases) was 0.44%. We calculated this rate by taking the ratio 
between the number of pregnant women reporting a birth 
defect and the estimated total number of timelines in our 
database in which we had access to the user’s tweets dur-
ing pregnancy (i.e., 196/44,825). Examples of birth defects 
included cleft lip, club foot, congenital heart defects, and 
Down’s syndrome. The frequencies of the consolidated birth 
defects reported in our cases are presented in Table 1. The 
categories used were based on Medical Dictionary for Regu-
latory Activities sub-classes.
3.1  Characteristics of Women
Women who gave birth to a baby with a birth defect had a 
diferent demographic proile than women who gave birth 
to baby without a birth defect. Cases were older, more likely 
to be Caucasian, and less likely to live in USA; cases were 
also more likely to have missing information on race and 
Table 1  Birth defects by 
the Medical Dictionary 
for Regulatory Activities 
(MedDRA)
The sum of the frequencies is slightly greater than the number of cases; this is because, in some of the indi-
vidual cases, the child had multiple birth defects and the defects belonged to diferent sub-classes
MedDRA sub-class of congenital, familial, and genetic disorders Frequency
Musculoskeletal and connective tissue disorders congenital 63
Cardiac and vascular disorders congenital 46
Gastrointestinal tract disorders congenital 45
Chromosomal abnormalities and abnormal gene carriers 21
Neurological disorders congenital 13
Renal and urinary tract disorders congenital 5
Eye disorders congenital 3
Respiratory disorders congenital 3
Skin and subcutaneous tissue disorders congenital 2
Blood and lymphatic system disorders congenital 2
Hepatobiliary disorders congenital 1
Reproductive tract and breast disorders congenital 1
Ear and labyrinth disorders congenital 1
3 Available at https ://www.babym ed.com/tools /retro -conce ption -birth 
day.
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less likely to have missing data on age. The distributions 
of age in both cases and controls are presented in Table 2 
and Fig. 2.
3.2  Timing and Type of Medication Intake
Cases reported taking some form of medication during 
pregnancy more frequently than the controls (35% vs. 17%) 
(Table 3). Many women, particularly in the cases, mentioned 
more than one medication intake or taking the same medica-
tion on more than one occasion (Table 4).
In the irst and third trimesters, the number of women 
taking medication among the cases was signiicantly higher 
than in the controls [odds ratio (OR) = 3.59 (1.44–10.13); 
p = 0.002 and OR = 2.22 (1.23–4.08); p = 0.004, respec-
tively]. In the second trimester, although a higher number of 
Table 2  Characteristics of 
the cases and controls among 
women who gave birth
IQR interquartile range
a p values were estimated using the chi-squared test
Characteristics Cases (n = 196) Controls (n = 196) p value,  diferencea
Age, years
 Median age (IQR) 23 (20–28) 21 (19–23) 0.0001
 Mean age (range) 25 (17–42) 22 (16–37) < 0.0001
 Women < 30, % 68 66 0.004
 Women < 35, % 80 70 0.04
 Missing data on age, % 14 28 0.0008
Race/ethnicity, %
 Caucasian 61 52 < 0.001
 Black 11 26
 Hispanic 6 11
 Asian 2 3
 Other 2 3
 Missing data on race 16 6
Place of residence, %
 USA 66 77 0.04
 UK 16 8
 Canada 4 3
 Other 2 3
 Missing data on place of residence 6 9
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Fig. 2  Age of the women who gave birth to a baby with a birth defect (cases) and without a birth defect (controls). CM women who gave birth to 
a baby with a malformation
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women among the cases took medications than the controls 
(22 vs. 12), this was not signiicantly diferent [OR = 1.94 
(0.89–4.43); p = 0.07].
When the analysis was restricted to women who reported 
taking medications during pregnancy, the pattern in timing 
of intake among the cases and controls was similar (Table 3). 
This is demonstrated by the fact that there is no statistically 
signiicant diference between the women taking any medi-
cation in the timing of their intake between the cases and 
controls (p = 0.1, p = 0.7, p = 0.9 for the irst, second, and 
third trimester respectively) (Table 3).
There were 53 diferent medications reported as taken in 
the timelines in the cases and 24 diferent medications men-
tioned in the control timelines. The number of women taking 
‘probably safe medications only’, ‘at least one potentially 
risky medication’, or ‘at least one unclassiied medication’ 
was higher in the cases than in the controls (42/196, 21% 
vs. 22/196, 11%, 14/196, 14% vs. 6/196, 3%, 12/196, 6% vs. 
6/196, 3%, respectively) (Table 3). If we limit our analysis to 
only those women who reported taking at least one medica-
tion, we ind that the pattern of intake by type of medication 
is very similar in the cases and controls (62% vs. 65%, 21% 
vs. 18%, 18% vs. 18%) [p = 0.9] (Table 3).
3.3  Predictors of Birth Defects
Using logistic regression, medication use was associated 
with a greater risk of birth defects [OR = 2.53; p < 0.001, 
95% conidence interval (CI) 1.58–4.06]. This result was 
not appreciably altered after adjusting for age, ethnicity, 
and country of residence. In multivariable models, the 
Table 3  Medication intake, 
timing, and type in the cases 
and controls
The ‘probably safe’ category consisted of A, B1, and B2 classiications and the ‘potentially risky’ category 
consisted of B3, C, D, and X as per the Australian categorization system (https ://www.tga.gov.au/presc ribin 
g-medic ines-pregn ancy-datab ase)
a p values were estimated using the chi-squared test
b ‘Among women taking medications’ means the denominator used was only those women who reported 
taking any medication as opposed to the whole group of women
c Multiple medications were taken by some women and some medications were taken more than once
d For some women, data from posts were missing in the irst and second trimester
Cases, % (n/N) Controls, % (n/N) p  valuea
Medication use
 Any medication use during pregnancy 35 (68/196) 17 (34/196) 0.0001
Timing of medication intake among women taking  medicationsb
 Any medication use during irst  trimesterd 42 (23/55) 23 (7/31) 0.1
 Any medication use during second  trimesterd 34 (22/65) 38 (12/32) 0.7
 Any medication use during third trimester 63 (43/68) 65 (22/34) 0.9
Type of medication intake among women taking  medicationsb
 ‘Probably safe’ medications  onlyc 62 (42/68) 65 (22/34) 0.9
 At least one ‘potentially risky’  medicationc 21 (14/68) 18 (6/34)
 At least one unclassiied  medicationc 18 (12/68) 18 (6/34)
Table 4  Percentage of instances of intake of ‘probably safe’, ‘poten-
tially risky’, and ‘unclassiied’ medications
The ‘probably safe’ category consisted of A, B1, and B2 classiica-
tions and the ‘potentially risky’ category consisted of B3, C, D, and 
X as per the Australian categorization system (https ://www.tga.gov.
au/presc ribin g-medic ines-pregn ancy-datab ase)
a Fisher’s exact t test
Instances 
in cases, % 
(n/N)
Instances 
in controls, 
% (n/N)
p  valuea
First trimester, N 27 8
 ‘Probably safe’ medication 67 (18/27) 63 (5/8) 0.70
 ‘Potentially risky’ medica-
tion
22 (6/27) 13 (1/8)
 ‘Unclassiied’ medication 11 (3/27) 25 (2/8)
Second trimester, N 39 14
 ‘Probably safe’ medication 61 (24/39) 64 (9/14) 0.75
 ‘Potentially risky’ medica-
tion
15 (6/39) 21 (3/14)
 ‘Unclassiied’ medication 23 (9/39) 14 (2/14)
Third trimester, N 60 26
 ‘Probably safe’ medication 73 (44/60) 77 (20/26) 0.93
 ‘Potentially risky’ medica-
tion
15 (9/60) 15 (4/26)
 ‘Unclassiied’ medication 12 (7/60) 8 (2/26)
Total pregnancy, N 126 48
 ‘Probably safe’ medication 68 (86/126) 71 (34/48) 0.97
 ‘Potentially risky’ medica-
tion
17 (21/126) 17 (8/48)
 ‘Unclassiied’ medication 15 (19/126) 13 (6/48)
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association between any medication use and the risk of birth 
defects was slightly reduced (OR = 2.34; p = 0.004, 95% CI 
1.24–4.44), but it remained highly signiicant (Table 5).
Conducting a one-factor analysis for age, ethnicity, and 
residence, we found that older women were more likely to 
report birth defects [age (per year): OR = 1.10, p < 0.001, 
95% CI 1.05–1.15] (Table 5). However, when ethnicity and 
residence were included in the model as categorical factors, 
ethnicity was statistically signiicant (p = 0.008), country of 
residence was not (p = 0.3). For both categorical variables, 
missing was included as a category, and caution must be 
taken in interpreting these results.
4  Discussion
We have demonstrated that there is a large amount of data 
publicly available on social media, speciically Twitter, from 
women during their pregnancy and on their pregnancy out-
comes, with many women posting on a daily basis. From 
these data, we created a prospective timeline for women 
posting on social media regarding their pregnancies. We 
were also able to extract information on birth defects, life-
style factors, and medication intake, including the frequency, 
timing, and type of medication use before and during the 
gestational period. However, the main results of the pilot 
study demonstrated a rate of malformations lower (0.44%) 
than the rate reported in the general population (3%), 
highlighting incompleteness and bias in social media data 
with respect to sensitive medical information such as birth 
defects.
Our analytic approach to social media data included a 
nested case-control study comparing exposures among 
women who gave birth to babies with a birth defect to 
women whose baby did not have a birth defect. We found 
that women who gave birth to babies with a birth defect were 
more likely to be older, Caucasian, and live outside of USA. 
Even after accounting for age, race, and place of residence 
between cases and controls, a higher medication intake was 
observed in pregnancies that reported birth defects. How-
ever, women who gave birth to babies with a birth defect 
also had a higher rate of missing data, limiting the causal 
inferences that can be made from this analysis. As automated 
methods for annotation of key demographic, medical and 
social data are further reined and validated, a nested case-
control study design will be the ideal study design to assess 
pregnancy outcomes from social media data sources because 
of the rarity of birth defects in the population [6].
There are a number of potential beneits of social media 
data as an alternative to pregnancy registries. First, even 
if the women may be identiied later in their pregnancies, 
data are collected prospectively, therefore reducing or 
eliminating recall bias. Other advantages are the potential 
availability of data on OTC medications, illicit drugs, and 
lifestyle factors such as smoking and alcohol that are not 
captured during routine healthcare encounters and other 
secondary data sources. Another beneit of social media 
Table 5  Odd ratios (95% 
conidence intervals) [ORs 
(95% CIs)] for birth defects 
by various demographic and 
lifestyle factors
ref reference
Variable OR (95% CI) [logistic regression estimates]
Univariable, unadjusted p value Multivariable, adjusted
for other variables
p value
Age (per year) 1.10 (1.05–1.15) < 0.001 1.09 (1.03–1.15) 0.002
Medication use
 Yes 2.53 (1.58–4.06) < 0.001 2.34 (1.24–4.44) 0.004
 No 1.0 (ref) 1.0 (ref)
Ethnicity
 Caucasian 1.0 (ref) < 0.001 1.0 (ref) 0.008
 Black 0.37 (0.21–0.65) 0.40 (0.21–0.79)
 Hispanic 0.57 (0.27–1.17) 0.86 (0.36–2.04)
 Asian 0.68 (0.18–2.60) 0.83 (0.25–1.55)
 Other 0.68 (0.18–2.60) 0.80 (0.19–3.48)
 Missing 2.27 (1.11–4.62) 3.42 (1.25–9.40)
Place of residence
 USA 1.0 (ref) 0.01 1.0 (ref) 0.3
 UK 2.28 (1.19–4.36) 1.97 (0.85–4.57)
 Canada 1.89 (0.60–5.90) 1.06 (0.22–5.03)
 Other 0.20 (0.02–1.65) 0.24 (0.01–4.43)
 Missing 1.73 (0.90–3.35) 1.69 (0.69–4.11)
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data is that a comparator group of unexposed pregnant 
women can be ascertained, which is often lacking in tra-
ditional registries. Additionally, although not the focus 
of our investigation, social media posts contained many 
adverse pregnancy outcomes, such as early pregnancy loss, 
low birth weight, and premature delivery, which are not 
the primary outcomes of interest in pregnancy registries.
Conversely, there are several drawbacks of social media 
data. First, there are potential diferences in key factors 
associated with birth defects when compared with the 
general population [36]. For example, the mean age of the 
cases and controls in this study was approximately 7 and 
9 years younger than the general population, respectively, 
although this may be a relection of the large number of 
women classiied as having a missing age [37, 38]. Other 
factors, such as the education levels and social class of 
social media users, may difer from the wider population. 
Additionally, the proportion of women reporting at least 
one medication use is low in both our cases and controls 
compared with other studies [2]. Finally, the rate of birth 
defects in the social media population was lower than the 
rate in the general US population [39, 40].
Reasons for the underestimation in the current study 
include the incompleteness or underreporting of key infor-
mation as a result of multiple factors, such as the fact that 
women may be less likely to report high-risk behaviors 
and women who are aware that their babies may have a 
birth defect may be less likely to discuss this informa-
tion on social media. Additionally, the Natural Language 
Processing method used to identify birth defects might 
not be able to capture all such mentions and requires 
further development. Many women did not allude to the 
birth defects in much detail or with as much frequency 
as would be expected given the detail in their other posts 
while pregnant. Some women also played down any birth 
defect, posting remarks such as “it’s no big deal but …”.
Recent reviews of traditional pregnancy registries con-
ducted by the US Food and Drug Administration have identi-
ied key challenges in the recruitment of patients including 
the reduced likelihood of women to continue to use drugs 
that may be associated with birth defects [41] and the wide-
spread use of early prenatal screening [8]. Social media 
have the potential to identify women for recruitment into 
traditional registries even prior to conception, women who 
are exposed and unexposed to the drug of interest, and to 
reduce the recall bias associated with key lifestyle and medi-
cal factors contributing to birth defects. This ability to target 
and recruit women from a larger pool would allow for the 
assessment of birth defects with greater statistical power, 
and the availability of non-exposed women provides greater 
clinical relevance to these statistical indings. The ethical 
issues around this active recruitment method need careful 
consideration [42]. It is anticipated that ethical approval and 
informed consent will be required to collect information in 
this manner and for its use for research purposes. Guidelines 
to help assist researchers to consider the ethical issues for the 
many diferent approaches to using social media in research 
are available and continue to be developed [42].
The information from social media could also be used 
to inform public health and health promotion campaigns. 
Some of the medications identiied among this study cohort 
are known to cause problems during pregnancy [43] and 
many have safer alternatives. The patterns of medication 
intake could be used to prioritize which medications should 
be highlighted as potentially unsafe during pregnancy in 
public health messages. For instance, the risks associated 
with the use of ibuprofen during pregnancy may not be 
understood by women. While data are mixed, non-steroidal 
anti-inlammatory drugs such as ibuprofen have been linked 
to an increased risk of spontaneous abortion and congeni-
tal malformations when taken in the irst trimester [43–45] 
and linked to renal impairment and cardiopulmonary abnor-
malities in the neonate when taken later in pregnancy [46]. 
Additionally, there have been reports on an increased risk of 
postpartum hemorrhage for women exposed to non-steroidal 
anti-inlammatory drugs [44].
4.1  Limitations
Automatic language processing methods utilized in this 
study enabled the selection of pregnant women from social 
media. These methods also facilitated the identiication of 
concepts of interest (birth defects, medication intake, and 
pregnancy timeframe) and greatly reduced the annotation 
efort. However, the manual annotation efort for the identi-
ication of birth defects, which was the primary focus of this 
study, still required 800 h to annotate over 100,000 tweets, 
which limited the ability to include a greater number of con-
trols for each pregnant case and to extract additional valu-
able information available within these tweets. The amount 
and detail of information disclosed in the pregnancy time-
lines was considerable and sometimes overwhelming. The 
amount of information varies from individual to individual, 
with some twitter users disclosing many personal thoughts 
to others who limit the personal information they choose to 
post. Twitter has recently increased the number of characters 
allowed on each post from 140 characters to 280 charac-
ters. This may increase the level of detail posted and lead to 
less ambiguous posts and improve data clarity, while also 
increasing the annotation burden. Additional methodologic 
challenges included the inability to match cases and controls 
by maternal age, despite age being the biggest risk factor for 
birth defects. Not all users had their age in their proile infor-
mation or posted in their tweets. Further automatic language 
processing advances are warranted to improve these methods 
and to develop new methods to automatically extract other 
 S. Golder et al.
relevant data from social media timelines (such as pregnancy 
outcomes, age, place of residence, race, and later substance 
use) for rapid safety surveillance. For example, automatic 
methods to determine age from a timeline would have facili-
tated a greater than 1:1 match between cases and controls. 
Additional research to develop automatic methods for detect-
ing birth defects through social media data is needed. With 
additional inputs and broader algorithms, we may be able to 
capture additional pregnancies with birth defects in future 
work.
5  Conclusion
In future research, the study design should ideally incorpo-
rate matching of cases and controls by key factors includ-
ing age, race, geography, gestational timeline, and volume 
of tweets to have greater certainty on conclusions drawn 
regarding associations between drug use and outcomes of 
interest. The speciic focus on matching on volume of tweets 
is to reduce the likelihood that key medical information 
would be missing and we need to consider how to reduce the 
chance of false negatives among the control arms. Further, it 
cannot be assumed that no mention of a birth defect or medi-
cation intake indicates that no such event occurred. There-
fore, a validation of cases of birth defects identiied through 
pregnancy timelines against diagnoses from medical records 
would provide additional certainty regarding the speciic-
ity and sensitivity for case ascertainment. The associations 
(positive or negative) derived from social media data should 
be validated against the association estimated from other 
data sources, including voluntary registries and claims/elec-
tronic healthcare record databases. These validation eforts 
will be required to use results from studies in social media 
data sources in submissions to regulatory agencies as an 
alternative to traditional voluntary registries. Other types of 
social media (particularly non-microblogging sites) should 
be investigated as diferent results may be obtained. Finally, 
future research is needed to determine in which scenarios 
social media data may be most informative, including for 
which drug types, frequency of exposure, and magnitude 
of association.
While social media data have their limitations, in this 
pilot efort, we have demonstrated that it is feasible to use 
Twitter data in assessing medication intake and birth defects; 
however, the information obtained cannot replace pregnancy 
registries at this time. With further reinement and valida-
tion, social media data could potentially complement other 
established methods in further characterizing the efects of 
drugs after introduction to the market, including populations 
underrepresented or not studied (i.e., pregnant women) in 
clinical development programs. Development of improved 
methods to automatically extract and annotate social media 
data may increase their value in supporting regulatory deci-
sion making regarding pregnancy outcomes in women using 
medications during their pregnancies
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